Fall Clinical Trials

19 recruiting

Fall Trials at a Glance

223 actively recruiting trials for fall are listed on ClinicalTrialsFinder across 6 cities in 52 countries. The largest study group is Not Applicable with 81 trials, with the heaviest enrollment activity in New York, Boston, and Philadelphia. Lead sponsors running fall studies include Mayo Clinic, M.D. Anderson Cancer Center, and National Cancer Institute (NCI).

Treatments under study

About Fall Clinical Trials

Looking for clinical trials for Fall? There are currently 19 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fall trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fall clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 223 trials

Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Merck Sharp & Dohme LLC770 enrolled164 locationsNCT06824467
Recruiting
Not Applicable

ALERT-ED: Awareness and Linkage to Resources for At-Risk Emergency Department Patients

High Fall Risk
University of Colorado, Denver20,700 enrolled1 locationNCT07028463
Recruiting
Phase 2

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc310 enrolled91 locationsNCT05128825
Recruiting
Not Applicable

Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device

VertigoHearing LossFall Prevention+4 more
Stanford University350 enrolled1 locationNCT05365646
Recruiting
Not Applicable

Steady Stride Fall Prevention Protocol vs Standard of Care

Fall PreventionFalls
Steady Strides: Fall Prevention and Stroke Rehabilitation Medical Institute102 enrolled1 locationNCT07092176
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled260 locationsNCT07213804
Recruiting
Phase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

Advanced Colorectal CarcinomaAdvanced Anal CarcinomaAdvanced Biliary Tract Carcinoma+41 more
Mayo Clinic220 enrolled2 locationsNCT05969860
Recruiting
Phase 3

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Stage III Ovarian CancerStage IV Ovarian CancerStage III Fallopian Tube Cancer+3 more
GOG Foundation220 enrolled59 locationsNCT05659381
Recruiting
Not Applicable

Health Promotion With Targeted Exercise Intervention for Decreasing Fall Risk and Inactivity in Aging Veterans With Obesity and Signs of Sarcopenia

SarcopeniaObesityFalls
VA Office of Research and Development50 enrolled1 locationNCT07206368
Recruiting
Phase 3

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

Primary Peritoneal CancerFallopian Tube CancerEpithelial Ovarian Cancer
Sichuan Baili Pharmaceutical Co., Ltd.384 enrolled1 locationNCT06994195
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Not Applicable

Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes

Cardiovascular DiseasesOsteoporosisType 2 Diabetes+2 more
Aalborg University Hospital490 enrolled1 locationNCT06745544
Recruiting
Not Applicable

Effects of Three Different Exercise Programs on Dynamic Balance in Community-Dwelling Older Adults

Balance DisordersAgingRisk of Falling in the Elderly
Fenerbahce University45 enrolled1 locationNCT07525453
Recruiting
Phase 1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Breast CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma+5 more
M.D. Anderson Cancer Center300 enrolled1 locationNCT03604315
Recruiting

Potential of Interface Care Models to Deliver More Appropriate Care to Patients With Acute Medical Illness

Chronic Obstructive Pulmonary Disease (COPD)PneumoniaInfection+6 more
National University Hospital, Singapore220 enrolled1 locationNCT07536035
Recruiting
Not Applicable

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Ovarian CancerFallopian Tube Cancer
M.D. Anderson Cancer Center100 enrolled9 locationsNCT05287451
Recruiting
Phase 1Phase 2

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Imunon30 enrolled4 locationsNCT05739981